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Abstract
Background: Chronic cyclic pelvic pain (CCPP) affects women’s quality of life and pituitary downregulation is often
used for symptomatic relief. However, prolonged suppression of ovarian function is associated with menopausal
side effects and can lead to osteoporosis. Currently, the use of gonadotropin releasing hormone agonists (GnRHa)
for treatment of CCPP is usually restricted to 6–9 months, limiting their efficacy. There is limited information
regarding safety and efficacy with longer-term use. The aim of this study is to examine the safety and efficacy of
long-term (24 months) pituitary down-regulation with the GnRHa (Triptorelin SR) with add-back therapy (ABT) using
Tibolone for symptom relief in women with CCPP.
Methods: A single-arm, prospective clinical trial at a Tertiary University Teaching Hospital of 27 patients receiving
Triptorelin SR (11.25 mg) and Tibolone (2.5 mg). Outcomes measures were the safety of treatment assessed by
clinical examination, haematological markers, liver and renal function tests and bone mineral density (BMD) at 12,
18 and 24 months as well as at 6 months post-treatment. Pain and health-related quality of life (HR-QoL) assessed
using the endometriosis health profile (EHP-30) and chronic pain grade (CPG) questionnaires.
Results: There was no evidence for any significant harmful effects on any of the measured haematological, renal or
liver function tests. Although results regarding the effect on BMD are not conclusive there is an increased risk of
development of osteopaenia after 12 months of treatment. Pain and HRQoL assessments showed significant
improvement during medication, but with deterioration after treatment cessation.
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Conclusion: Long- term Triptorelin plus Tibolone add-back therapy in women suffering from CCPP does not
appear to be associated with significant serious adverse events apart from the possibility of deterioration in the
BMD that needs to be monitored. This mode of therapy appears to be effective in pain relief and in improving
quality of life over a 24-month period.
Trial registration: Clinical trials database NCT00735852.
Keywords: Endometriosis, Chronic cyclic pelvic pain, GnRH, Add back therapy
Background
Chronic pelvic pain (CPP) is a common problem that af-
fects many women. Estimates of prevalence vary be-
tween 4.0 and 43.4% of women globally [1, 2]. CCPP is
considered to be one of the most debilitating conditions
affecting women of childbearing age [3] and can have a
negative impact on a women’s quality of life and ability
to function, causing significant loss of time from work,
psychological distress and impaired sexual function [4].
In cases of chronic cyclic pelvic pain (CCPP) the pain
is synchronous with the menstrual cycle and is usually
related to the cyclic fluctuations in ovarian hormones.
Often such pain may be a result of gynaecological condi-
tions such as endometriosis or adenomyosis but in some
instances the pain can be non-gynaecological in nature.
For instance, CCPP can be the result of neurological or
musculoskeletal causes [5–7], gastrointestinal tract con-
ditions such as irritable bowel syndrome [8] or urinary
tract conditions such as interstitial cystitis [9]. In many
cases, there is no clear diagnosis, presenting a clinical di-
lemma and limiting the options that can be offered.
In determining the most effective treatment for chronic
cyclical pelvic pain and endometriosis, many factors must
be considered including the severity of symptoms and ef-
fect on quality of life (QoL), the feasibility of surgery and
associated surgical risk, the patient’s need for future fertil-
ity and tolerance to treatment side effects [10].
Pituitary downregulation with gonadotropin releasing
hormone agonists (GnRHa) is often used to treat women
with severe CCPP who are not trying to conceive [11, 12],
where simple analgesics and progestogen therapy are not
effective and where surgical intervention is not feasible,
deemed too high risk or not the patient’s preference.
Prolonged administration of GnRHa initially causes pi-
tuitary stimulation followed within a few days by pituitary
desensitisation due to persistent occupation of GnRH re-
ceptors by the long-acting synthetic GnRHa, preventing
normal receptor recycling. This results in a rapid decrease
in the circulating concentrations of FSH and LH [13] with
profound suppression of ovarian steroid secretion within
two weeks of starting treatment [14].
A maximum of 6months of treatment with GnRH ana-
logues such as Triptorelin is currently licensed for ovarian
downregulation [15, 16]. This is due to the potential for
reduction in bone mineral density (BMD) that follows
prolonged periods of hypo-oestrogenisation [13, 17]. The
rate of loss of bone density is in the range of 0.5–1.0% per
month, which over time increases the risk of osteoporosis
[18]. Restriction of use of GnRHa to 6–9months severely
limits clinical efficacy: no sooner has the patient derived
maximum benefit from the treatment than she is advised
to stop. However, several studies have shown the efficacy
of hormone replacement “addback” therapy prescribed in
conjunction with GnRHa to reduce the impact of low cir-
culating oestrogens on bone density. The principle of add-
back therapy is based on the “oestrogen threshold”
hypothesis, aiming to increase circulating oestrogen con-
centrations to a level sufficient to sustain bone integrity
and prevent menopausal side effects but not sufficient to
stimulate growth of endometrial tissue or cause recur-
rence of pain [16, 18]. Many patients with severe CCPP re-
spond well to GnRHa but experience rapid symptom
recurrence on cessation of treatment, and would benefit
from prolongation of therapy [19]. Clinical data regarding
the long-term safety and efficacy of GnRHa beyond 6
months is currently lacking.
In this study, we therefore examine the safety and effi-
cacy of prolonged ovarian downregulation for 24 months
using the GnRH, Triptorelin in combination with Tibo-
lone addback therapy. Tibolone is a synthetic molecule
which combines oestrogenic, progestogenic and weak
androgenic actions and is commonly used for addback
with GnRHa [20].
We assessed the efficacy of this combination therapy
used over a 24-month period, studying the effects on
both chronic pelvic pain symptoms and quality of life
along with regular assessment of BMD and other
markers of clinical safety.
Methods
The study was a single-centre, single-arm, open-label
prospective clinical trial to evaluate the efficacy and
safety of extended treatment (24 months) with Triptore-
lin (Gonapeptyl® SR) 11.25 mg every three months ad-
ministered in combination with Tibolone (Livial®) tablets
2.5 mg daily for the treatment of women with CCPP. As
the study included within-patient comparisons, there
was no control arm and all patients received the same
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active treatment. Thirty-one premenopausal patients aged
20–45 with CCPP who attended the gynaecology clinic at
the Jessop Wing, Sheffield Teaching Hospitals, Sheffield,
UK, and who satisfied the inclusion/exclusion criteria
were recruited for the study from December 2008 with
the last participant completing the study in May 2016.
Women were included if they were aged between 18
and 45 years inclusive with a clinical diagnosis of CCPP
defined as suffering from pelvic pain, strongly related to
the menstrual cycle, severe enough to interfere with
daily activity and of at least 6 months duration (with or
without endometriosis). Participants must have had in-
vestigations for possible endometriosis within three years
prior to the screening visit (laparoscopy or ultrasound).
All women must have had regular menstrual cycles (be-
tween 24 and 42 days) for the 3 months prior to screen-
ing and must be able to understand, and willing to
comply with the requirements of the protocol.
Exclusion criteria
Patients were excluded if they had received treatment with
any GnRH analogues within 6months prior to screening,
treatment with Danazol, Gestrinone or Cyproterone acetate
within the 6months prior to screening or anticipated require-
ment during the study, treatment with cyclical progestogens
or combined oral contraceptives within one full menstrual
cycle prior to screening, or anticipated requirement for these
treatments during the study period and finally treatment with
any other medication for CCPP (other than simple analgesics)
within three months prior to screening.
Patients were also excluded if they had continuous or
acyclic pelvic pain, metabolic bone disease, unexplained va-
ginal bleeding or any other medical condition that in the
opinion of the investigator would impact upon the safety or
efficacy of the study treatment or any study assessments.
The presence of an abnormal full blood count (FBC),
liver or renal functions at screening or within the 6
months prior to screening or having a Bone mineral dens-
ity (BMD) age adjusted T-Score of − 2 or below at the
screening visit were also indications for exclusion from
the study. Women were also excluded if they were receiv-
ing concomitant treatment with Coumarin or Indanedione
derivatives or had a known contraindication, allergy or
hypersensitivity to any of the test compounds or materials
(including both Triptorelin® SR and Tibolone).
Finally, patients were excluded if they were pregnant or
lactating, planning a pregnancy within 31months of
screening, unwilling to use adequate barrier contraception
for the duration of the study, had received any investiga-
tional drug therapy within 30 days prior to the study, were
scheduled to receive such a drug during the study period
or had previously entered this study. Patients of child-
bearing potential (i.e. who are not surgically sterile) must
have a negative urine pregnancy test at the baseline visit.
Patients who fulfilled the inclusion/exclusion criteria
and agreed to participate in the study attended for a
screening visit at which the patient’s medical history was
reviewed, vital signs were documented and blood samples
were collected for routine haematology and biochemistry
analysis. Any previous or concomitant medications were
recorded. The patient was given a diary and instructed on
its completion. Bone density was determined using a dual-
energy x-ray absorptiometry (DEXA scan) conducted ei-
ther at the screening visit or in the interval between the
screening and baseline visits. Within two months of the
screening visit, patients who fulfilled the inclusion/exclu-
sion criteria returned to the clinic for the baseline visit. At
this visit a physical check and urine pregnancy test were
performed, vital signs were measured, pain and Health Re-
lated Quality of Life (HR-QoL) questionnaires were com-
pleted. Patients who were considered eligible for the trial
received an injection of Triptorelin® SR 11.25mg in the
late luteal phase of the menstrual cycle, and were given
enough Tibolone® 2.5 mg tablets to cover the time period
until the following study visit. The diary given at the
screening visit was collected and reviewed and patients
were given a new diary card.
Patients returned for repeat Triptorelin injections
every three months until month 21 at which point the
last Triptorelin injection was administered. At these
visits, patients were also dispensed additional amounts
of Tibolone. Patients were required to return their used
Tibolone packaging and any remaining pills at every
study visit. These were checked to validate compliance.
At each injection visit, the completed patient diary was
collected and a further patient diary dispensed.
Follow-up assessments were conducted at 6, 12, 18 and 24
months following the baseline visit. An end of study follow-
up evaluation was conducted six months after the end of the
24-month treatment period of the study (at month 30). At
every follow-up visit HR-QoL questionnaires were given. Vital
signs, bone density assessment DEXA and haematology and
biochemistry analysis were repeated at months 12, 24 and 30.
The physical examination was repeated at months 24 and 30.
The reasons and numbers of drop outs over the course of the
study is seen in Table 1. A Gant chart of procedure per-
formed at each visit is seen in Table 2.
Outcomes measures
1. Safety Outcomes:
a. Significant change in any of the parameters of the
full blood count, liver and renal function tests over
the course of the study.
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b. Change in the bone mineral density (BMD) as
assessed by Dual Energy X-ray absorptiometry for
both the lumbar spine (L1-L5) and proximal femur.
For consistency, the patient’s scan was performed
on the same machine for the duration of the study.
Osteopaenia was defined a decrease in the T score
by 1–2.5 SD while osteoporosis was defined a de-
crease in the T score by 2.5 SD or more.
c. Occurrence of adverse events (AEs): All adverse
events occurring over the course of the study were
recorded. An adverse event was defined as any
unfavourable medical episode occurring during the
course of the study which may or may not be
related to the study medications. Adverse events
were classified as related or unrelated to the
treatment medications. In addition, they were
classified according to severity into:
a. Mild: symptoms do not alter patient’s healthy
functioning.
Table 1 Number and reason for drop outs at each visit
Clinical visit (n) Drop out (n)
Screening (n = 31) Failed screening (n = 2)
Lost to follow up (n = 1)
Withdrawal of consent (n = 1)
Baseline (n = 27) No longer eligible (n = 1)
Withdrawal of consent (n = 1)
3 months (n = 25) Intolerable menopausal symptoms (n = 1)
No improvement in symptoms (n = 2)
6 months (n = 22) No improvement in symptoms (n = 1)
9 months (n = 21) Wishing to conceive (n = 1)
No improvement of symptoms (n = 1)
12 months (n = 19) Wishing to conceive (n = 1)
No improvement of symptoms (n = 1)
15 months (n = 17) Intolerable menopausal symptoms (n = 2)
18 months (n = 15) Intolerable menopausal symptoms (n = 1)
Lost to follow up (n = 1)
24 months (n = 13) No further drop outs
Table 2 Summary of procedures performed during the study visits. The study divided into three phases; screening, treatment and
post-screening phase which distributed into 11 visits where each visit had certain evaluation measurements
Screening
phase
Treatment phase
Triptorelin SR 11.25 mg injected 3-monthly starting at baseline.
Tibolone 2.5 mg tablet taken daily from baseline.
Follow-up
phase
Visit 1 Screen Visit
22
Visit
3
Visit
4
Visit
5
Visit
6
Visit
7
Visit
8
Visit
9
Visit
10
Visit 11
Written informed consent X
Medical history X
History of CCPP X
Physical examination X X X
Vital signs 5 X X X X X
Urine pregnancy test X
Review of Inclusion / Exclusion Criteria X X
Enrolment in the study X
Bone density (DEXA) X X X X
CPG questionnaire X X X X X X
EHP-30 questionnaire X X X X X X
Blood samples for haematology and
biochemistry
X X X X
Triptorelin injection X X X X X X X X
Dispense Tibolone X X X X X X X X
Tibolone compliance checked X X X X X X X X
Dispense patient diary X X X X X X X X X X
Collect patient diary X X X X X X X X X X
Prior and concomitant medications X X X X X X X X X X X
Adverse events X X X X X X X X X X
End of study details X
1 Screening was conducted up to 2-months prior to the baseline visit. Screening and baseline visits were combined if the results of the DEXA scan were available
for review prior to enrolment.
2 The baseline visit took place in the late luteal phase of the patient’s menstrual cycle.
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b. Moderate: symptoms provide some degree of
impairment to function, but are not hazardous.
c. Severe: symptoms are hazardous to well-being,
serious impairment of function or
incapacitation.
d. Serious Adverse Events (SAEs): A serious adverse
event was defined as any event which results in
death or life-threatening events, or which results in
patient hospitalisation or prolongation of existing
hospitalisation. Any SAEs were reported immedi-
ately (within 24 h), independent of the circum-
stances or suspected cause, to the research nurse or
the Principle Investigator.
1. Efficacy Evaluations
Two quality of life questionnaires were used to exam-
ine the efficacy of treatment and effect on Quality of life
(QoL), the Chronic Pain Grade questionnaire and the
Endometriosis Health Profile 30.
a. Chronic pain grade (CPG)
This was developed in 1992 [21] and designed to as-
sess the severity of chronic pain problems. The CPG is
based on measures of pain intensity and pain-related dis-
ability and has been extensively validated [21, 22]. The
CPG consists of seven items providing a score which en-
ables chronic pain to be classified into one of four hier-
archical categories based on pain intensity and disability:
• Grade I – low disability, low pain intensity.
• Grade II – low disability, high pain intensity.
• Grade III – high disability, moderately limiting.
• Grade IV – high disability, severely limiting.
In addition to the categorical grading scheme above,
the CPG contains numerical self-rating scales for charac-
teristic pain intensity and disability scores. At each as-
sessment time point, patients were asked to consider
historical pain over the past six months
a. The Endometriosis Health Profile-30 (EHP-30):
The Endometriosis Health Profile-30 consists of a core
questionnaire containing 30 items and five scales: pain,
control and powerlessness, emotional well-being, social
support, and self-image. There are also six additional
modular scales: work, intercourse, relationship with chil-
dren, the medical profession, treatment, and infertility.
EHP-30 scale scores are standardised on a range of 0 to
100. The mean score per category and the global score
were calculated. A lower score indicates better health
status. The EHP-30 has been shown to be responsive to
change in patients with endometriosis and is more sensi-
tive to change than the generic questionnaire 36-item
short form health survey (SF-36) [23].
The primary efficacy criterion was the change in
Chronic Pain Intensity Score (CPI) at Month 12 in com-
parison with the Baseline visit while the secondary end-
points were changes in the individual assessment
questionnaires at each visit compared to the baseline.
Sample size determination
Assuming that Chronic Pain Intensity Score (CPI) at
Month 24 is the primary endpoint, in a previous 18-
month study with Zoladex, a 5.6 decrease at month 18
from baseline was observed (SD = 2.08). Aiming to dem-
onstrate 2 points decrease and assuming conservatively
that the corresponding SD = 3, based on a two sided 5%
alpha level and a power of 90%, 26 patients would need
to be included (based on a paired t-test). Allowing for a
dropout rate of 35%, a total of 40 patients were aimed to
be included in the study.
Statistical analysis
Anonymised data were analysed using the Statistical
Package for Social Sciences (SPSS, version 22; Chicago,
IL). Demographic data were expressed as mean (SD) or
median (range) as appropriate. Within group analysis
was performed using Wilcoxon signed-rank tests. A
Bonferroni correction was used as appropriate. Chi-
square analyses and Fisher’s exact tests were used to
study categorical variables. P values of < 0.05 were con-
sidered significant.
Results
Study population
Between December 2008 and May 2016, 31 patients with
CCPP were enrolled out of 193 approached for the
study. Thirty-one patients were consented and of these
27 participants commenced the study. The mean (± SD)
age was 33.35 (± 7.3) years and the mean (± SD) BMI
was 27.42 (± 5.9) kg/m2. Seventy four percent of the
study population had a diagnosis of endometriosis. Pre-
dominant presenting symptoms of the study population
are seen in Table 3.
Safety outcomes
Haematological profile
All values for haematological parameters can been seen
in Table 4. Results show comparison for values between
baseline and 12 months, baseline and 24months, 12
months and 24months and between 24 and 30 months.
Wilcoxon ranked test was used with Bonferroni correc-
tion (p < 0.0125).
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Liver function tests
Compared to baseline, results at 24 months showed no
significant changes in the mean (± SD) ALT {24 U/L (±
7.53) vs 28 U/L (± 21.84)} p = 0.05 or AST {22.77 U/L (±
4.75) vs 21 U/L (± 7.35) p = 0.33}. There was a significant
transient increase in the ALT concentration at 12
months however the concentration still remained within
the normal range {26.15 U/L (7.53), Bonferroni adjusted
p < 0.0125}.
Renal function tests
Compared to baseline, results at 24 months showed no
significant changes in the mean (± SD) concentration of
urea {4.73 mmol/L (± 0.88) vs 4.18 mmol/L (± 1.07) p =
0.67} or creatinine {68.31 mmol/L (± 12.9) vs 64.15
mmol/L (± .82) p = 0.23). There was also no significant
change at any other point in the study.
Bone mineral density
Lumbar spine
Although there was no evidence for a significant change
in the median (range) T score for the lumber spine over
the course of the study {baseline 0.1 (− 1.7–2.1), 12
months − 0.5 (0.0–1.0) and 24months − 0.3 (0.0–1.0, (p =
0.9}, there was a significant increase in the prevalence of
osteopenia by 12months (Chi square = 19.71, p < .001).
Six participants started the study with evidence of osteo-
paenia. Data was available from 5 of these six participants
at 12months, 3 participants at 24months and 2 partici-
pants at 30months. Data from the two osteopaenic partic-
ipants who completed the study showed that one
remained osteopaenic and the other had developed osteo-
porosis by the 30-month visit. For other participants who
started the study with normal BMD. One developed
osteopaenia by 12months and remained osteopaenic by
30months. One developed osteopaenia by 24months and
remained osteopaenic by 30months one more participant
developed osteopaenia by 30months.
Femoral region
There was no evidence for a significant change in the
median (range) T score for the proximal femur over the
course of the study {baseline 0.45 (− 1.4–2.4), 12 months
0.3 (0.0–1.0) and 24months 0.4 (0.0–1.0), p = 0.9}. Four
participants started the study with evidence of
osteopaenia (2 of these participants also had osteopaenia
of the lumbar spine). Only one of these participants
completed the 30 month follow up and continued to be
osteopaenic. The two other participants reached the 12
month follow up, where one was osteopaenic (the same
participant had osteopaenia of the lumbar spine and de-
veloped osteoporosis of the lumbar spine by the comple-
tion of the study). The remaining participant had
normal BMD. None of the participants who started the
study with normal femoral BMD developed osteopaenia
or osteoporosis.
Adverse events: Study specific adverse effects are listed
in Table 5. There were no reported serious events re-
lated to the study medications.
Efficacy assessments
Health-related quality of life (EHP-30 questionnaire)
Core questionnaire
a. Pain domain: There was a significant improvement in
the median (range) of the pain score at the 24months
follow up compared to baseline {7.9 (0–61.4) and 56.8
(.0–95.5)} respectively (Z = 3.301, p < 0.001). This was
followed by a significant deterioration after
discontinuation of treatment at the 30-month visit
{40.9 (0–75)} (Z = − 2.51, p = 0.009).
b. Powerlessness domain: There was a significant
improvement in the median (range) score at 24
months compared to baseline {14.8 (0–78.5) and 75
(0–100) respectively} (Z = − 3.16, p < 0.001). This
again significantly deteriorated after discontinuation
of treatment at the 30-month follow up {54.2 (0–
91.7)} (Z = − 2.45, p = 0.006).
c. Emotional well-being domain. There was a signifi-
cant improvement in the median (range) score by
24 months when compared to baseline {8.3 (0–50)
and 54.2 (0–100) respectively} (Z = 3.301,
p < 0.001). This again significantly deteriorated after
discontinuation of treatment at the 30-month fol-
low up {45.8 (0–70.8)} (Z = − 2.51, p = 0.009)
d. Social support and self-image domains: There was a
significant improvement by 24 months when com-
pared to baseline {(6.2 (0–75) and 50 (0–93.6)} re-
spectively (Z = − 2.79, p = 0.003). There was no
evidence for a significant change in the self-image
domain at 24 months compared with baseline {(37.5
(0–100) and 58.33 (0–100) respectively} (Z = − 1.92,
p = 0.054). There was no significant change in either
of these domains after discontinuation of treatment
by the 30-month follow up.
Modular questionnaire
a. Work domain: There was a significant
improvement in mean (median) score by 24 months
Table 3 Clinical characteristics of the study population
Predominant symptom Percentage
Severe dysmenorrhea 85.2%
Moderate dysmenorrhea 14.8%
Severe dyspareunia 18.5%
Moderate dyspareunia 29.6%
Mild dyspareunia 3.7%
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compared to baseline {0 (0–60) and 45 (0–85)}
respectively (Z = − 2.54, p = 0.008). There was a
significant deterioration after discontinuation of
treatment at the 30-month follow up {40 (0–90)}
(Z = − 2.21, p = 0.03).
b. Other domains: There was no evidence for a
significant change in the “feeling of frustration with
the medical profession”, “quality of sexual
intercourse” “relationship with children” and
“infertility” domains by the end of the study
Changes in EPH-30 domain scores are seen in Table 6.
Chronic pain grade questionnaire
Over the course of the study and compared to baseline,
there was a significant improvement in the pain inten-
sity, disability and pain grade scores (Table 7).
At 30 months and after discontinuation of treatment
there was a significant deterioration in the median
(range) pain intensity and disability scores (compared to
24months) {56.66 (6–80), p = 0.001 and 30 (0–66.7), p =
0.001} respectively.
Discussion
The licenced use of GnRHa for endometriosis is limited
to six months in the UK, although in many cases they
are needed for longer durations, particularly when surgi-
cal intervention is deemed non-feasible. The result of
these restrictions is that for those women who gain
benefit from the agonist, treatment must be withdrawn
almost as soon as it has become effective. This is a cause
of frustration and for both patients and clinicians. New
data on long term safety, particularly with respect to im-
pact on bone mineral density, are therefore needed.
Although many studies have examined the efficacy of
GnRHa for CCPP and endometriosis over periods of up
to six months [24], 12 months [18] and 18months [25],
to the best of our knowledge this is the first study to
provide data regarding both safety and efficacy of
GnRHa for a long-term 24-month period in women with
CCPP.
The study design with longitudinal six monthly follow-
ups allowed for the gathering of detailed information re-
garding changes that occur beyond the usual licensed
use, the temporal relationship of these changes as well
as an assessment of overall compliance with long term
therapy. The study also provides information regarding
quality of life and safety parameters up to 6 months after
completing a 24-month therapeutic course.
The first result of this study was that there was a sig-
nificant improvement in pain related QoL parameters
that continued throughout the duration of the study but
significantly deteriorated after cessation of the medica-
tion. The effects of CCPP and endometriosis on QoL
have been reported in many previous studies [26–30].
We used the well-validated quality of life instrument
EPH-30 to assess the benefits of long term GnRHa on
patient symptoms. We found that GnRHa plus addback
treatment led to a significant improvement in quality of
life and in pain scores by six months of therapy. How-
ever, other modules, including those assessing relation-
ship with children, sexual intercourse and infertility did
Table 4 Comparison of haematological parameters at different points in the study. Values are expressed as median (range)
Baseline p* 12months p** 24months p*** 30 months p****
HCT 0.39(0.33–0.47) 0.008 0.42(0.36–0.47) 0.74 0.42(0.38–0.46) p < 0.001 0.41 (0.37–0.46) 0.16
RBCs 4.48 (3.66–5.13) 0.008 4.67(3.66–5.13) 0.42 4.77(4.20–5.62) P < 0.001 4.6 (4.14–5.23) 0.07
Neutrophils 4.8 (2.10–9.50) 0.042 4.1(1.40–6.86) 0.16 3.5(0.31–6.12) p = 0.007 4.31(3–6.56) 0.18
Monocytes 0.54 (0.20–1.10) 0.009 0.45(0.24–0.70) 0.18 0.46(0.30–0.60) p = 0.34 0.53 (0.30–0.91) 0.13
p* baseline vs 12months.
p** 12 months vs 24months.
p*** baseline vs 24 months.
p**** 24months vs 30 months.
Table 5 Adverse events that could be related to the treatment
Adverse event Number of episodes Categories of the adverse events Number of patients affected
Vaginal bleeding 23 Reproduction 13
Depression 2 Psychiatric disorders 2
Loss of libido 2 Psychiatric disorders 2
Mood swings 1 Psychiatric disorders 1
Hot flush 10 Vascular 9
Night sweats 2 Skin disorders 2
Pain at injection site 2 General Disorders 1
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not show a significant change. This may be due to the
fact that not all patients had children, were sexually ac-
tive or were trying to conceive. Patients wishing to con-
ceive were excluded from the study as GnRHa inhibit
ovulation rendering the patient temporarily infertile.
Other modules, such as the patients’ feelings of frus-
tration about the treatment and about the medical pro-
fession, did not show significant improvement. This
could be due to the chronic nature of the condition
which may have influenced the patients’ feelings regard-
ing possible long-term cure and creating an element of
pessimism regarding full cure [31]. Physicians treating
patients with CCPP should be aware of the psychological
dimensions that often form a large part of the patient’s
problems, and consider referral for counselling regarding
long-term prognosis and management, particularly after
discontinuation of GnRHa treatment.
Regarding the safety of administration of GnRH ana-
logues and add back therapy beyond the licensed 6-
month period, we found no evidence for a significant ad-
verse effect on haematological parameters, liver or renal
functions associated with 24months of treatment. The
only significant change was an increase in RBC and haem-
atocrit which is probably as a result of the temporary state
of pseudo-menopause leading to the cessation of menstru-
ation. Cessation of menses may also have contributed to
the improvement in the quality of life parameters seen in
this study, since many patients initially presented with
dysmenorrhoea so it would be expected that the cessation
of menstruation would have a positive effect.
Although ALT concentrations did show a significant
change after 12 months of the study, this change seemed
to be temporary as it resolved by the 18month follow
up. Furthermore, despite this change, ALT concentra-
tions always remained within the normal range and
there were no observed changes in other liver enzymes
during the study. Again, this transient change in ALT
may be due to the pseudo-menopausal state, as similar
changes in ALT concertation have previously been re-
ported in menopausal females [32].
The principal concern when using long-term GnRHa
relates to loss of BMD [18, 25]. This study suggested a
risk of deterioration in BMD with prolonged use of
GnRH despite the use of Tibolone add back therapy.
There are several important points to note in this regard.
Firstly, a significant number of patients started the study
with already compromised BMD (i.e. osteopaenia) and it
is one of these patients who developed osteoporosis by
the end of the study. For those who developed osteope-
nia for the first time during the study (14%), it is import-
ant to note that the osteopaenia persisted at the 30
month follow up (i.e. 6 months after discontinuation of
the GnRH therapy). Furthermore, since some of these
patients did not complete the study or were lost to fol-
low up, it is unclear whether any of them had improved,
stabilised or deteriorated BMD at the 30months follow
up. It is of course expected that any loss of bone mineral
density was mitigated by the use of tibolone. Without a
control arm where tibolone was not prescribed, it would
be impossible to quantify such a benefit. Such a study
design however would be ethically questionable.
Finally, the risk of developing osteoporosis with pro-
longed GnRHa therapy is often less than the significant
additional surgical risk associated with operating on
such patients. In many cases surgically removing the
ovaries (with or without hysterectomy), when
Table 6 Comparison of baseline EPH-30 domain scores at other points of follow up (baseline versus 6, 12 and 18 month visits).
Values are expressed as median (range) with respective p values
Baseline 6 m p 12m p 18m p
Pain domain 56.8 (0–95.5) 19.3(0–90.9) < 0.001 11.4 (0–72.7) < 0.001 9.08(0–56.8) < 0.001
Control and powerlessness 75 (0–100) 16.7(0–100) < 0.001 16.7(0–100) < 0.001 14.3(0–79.2) < 0.001
Emotional well-being 54.2 (0–100) 18.7(0–95.8) 0.01 25.4(0–75) < 0.001 20.8 (0–68.3) < 0.001
Social support 50 (0–93.6) 15.6 (0–39.5) 0.03 12.5(0–93.7) < 0.001 12.5(0–100) 0.006
Self-image 58.3 (0–100) 22.5(0–100) 0.004 33.3(0–100) < 0.001 33.3(0–91.7) 0.001
Work domain 45 (0–85) 12.5(0–80) 0.91 0 (0–80) 0.004 0 (0–70) 0.001
Table 7 Comparison of baseline CPG domain scores versus 6, 12 and 18 month visits. Values are expressed as median (range) with
respective p values
Baseline 6 m p 12m p 18m p 24m p
Pain intensity 66.6 (30–93) 39.9 (0–83.3) 0.001 30
(0–76.7)
< 0.001 30 (0–73.3) p < 0.001 13.33
(0–36.3)
< 0.001
Disability 60
(16–113)
16.7 (0–93.3) 0.002 0 (0–66.7) < 0.001 0 (0–63.3) p < 0.001 0 (0–63) 0.001
Pain grade 3 (1–4) 1 (0–4) 0.004 0 (0–4) 0.001 0 (0–4) p < 0.001 0 (0–4). 0.002
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appropriate, would subject the patient to similar risks re-
garding BMD even if HRT were used. It is therefore im-
portant to weigh the risks of both approaches. This
study therefore emphasises the importance of regular
follow up of BMD in patients on prolonged GnRH ther-
apy. Furthermore, a baseline scan performed prior to
starting treatment may screen for patients who already
have compromised BMD and therefore are at higher risk
and require closer follow up. It would also be of interest
to examine the use of higher dose oestrogen add back
regimens in future studies, since this approach may offer
better protection against loss of BMD without com-
promising the efficacy of the GnRHa therapy on pain. It
would also be interesting to examine the use of different
add-back therapy drug delivery systems such as the use
of oestrogen patches which are known to be associated
with increased oestrogen plasma concentration due to
the avoidance of the hepatic first-pass effect [33].
No Serious Adverse Events occurred during the study.
Some Adverse Events did occur, which may have af-
fected compliance and contributed to the dropout rate.
Nevertheless, these AEs occurred in only few patients
and for only a few episodes. It is difficult to ascertain
whether commonly reported Adverse Events such as
headaches were the result of the medication or due to
some other non-related condition [34]. It has been re-
ported that the mere presence of endometriosis may be
associated with such symptoms as result of hormonal
fluctuations [35–37].
The current study is not without limitations. Although
we aimed to recruit a larger number of women, this
proved to be logistically difficult. Despite the large num-
ber who were screened (193 women), only 31 provided
consent to participated and of these 27 started the study.
The study also had a significant drop out rate. These is-
sues however were expected due to the very nature of
the condition, the length of the study and the demo-
graphics of the study population. For example, it is ex-
pected that there would be fluctuations in severity of
CCPP which may affect compliance. Furthermore, in
such a relatively young group priorities may shift. For
example, a desire for fertility or a change in work cir-
cumstances requiring a move to another location as well
as the psychological effects of long term pelvic pain and
the need of long term therapy may affect patients’ mo-
tivation and compliance with treatment. Nevertheless,
we believe that our results are a benefit to clinicians who
wish to use this approach since it informs them that (a)
the medications will not work in 100% of women who
start treatment and (b) frequent follow up and
reinforcement is necessary to maintain good compliance
with treatment. Involvement of the multidisciplinary
team with input from nurse practitioners and psycholo-
gists is helpful here.
Secondly, additional confounding factors influencing
the rate of bone metabolism such as lifestyle (exercise,
alcohol, smoking and caffeine consumption) and genetic
factors were not analysed in this study. Furthermore, in
future studies when analysing changes in the BMD over
time, values should be adjusted for advancement of bone
age over the course of the study (30 months = 2.5 years)
to account for the excepted 1% annual loss in BMD [38].
Self-reporting questionnaires were used in this study
and although these were well validated, self-reporting
has disadvantages due to the influence of personal atti-
tudes and beliefs particularly when reporting on do-
mains such as sexual behaviour. Finally, further studies
are now needed to explore safety and efficacy beyond 24
months of therapy in order to provide women with an
even longer-term solution which may truly influence
their attitude.
In conclusion, the use of long- term Triptorelin plus
Tibolone as add-back therapy in pre-menopausal women
suffering from CCPP and endometriosis does not appear
to be associated with significant serious adverse events
apart from the possibility of deterioration in the BMD that
needs to be monitored. This mode of therapy appears to
be highly effective in pain relief and in improving quality
of life over a 24-month period. Further prospective studies
are needed to assess other means of protecting BMD dur-
ing long-term GnRHa treatment and to use metabolic pa-
rameters such as serum bone alkaline phosphatase
(sBAP), serum N-terminal telopeptide of type I collagen
(NTX), in addition to the DEXA scan to determine the
optimum treatment period for individual patients. We
hope that the findings of this study will help change the
existing licencing restrictions on the duration of GnRHa
therapy and help shape National and International guide-
lines regarding the treatment of this group of women who
often have limited alternate options.
Acknowledgements
The authors would like to acknowledge the contribution of Ipsen who
provided the Triptorelin and Organon Laboratories Ltd. who provided the
Tibolone free of charge.
Authors’ contributions
SA contributed to data gathering, statistical design and analysis, and wrote
the main draft of the manuscript. SD had primary responsibility for
recruitment into the study and data gathering. WLL set up the study and
was the first Principle Investigator. GJ designed the Quality of life analysis
aspect of the study. MM was the second Principle Investigator contributing
to the statistical analysis, design and interpretation of the results and writing
the manuscript. All authors contributed to the drafting and critical appraisal
of the work and provided final approval of the manuscript and all authors
share accountability for this work.
Funding
This paper presents independent research supported by the National
Institute for Health Research (NIHR) through the NIHR affiliated Clinical
Research Facility (CRF) at Sheffield Teaching Hospitals.
Alshehre et al. Reproductive Biology and Endocrinology           (2020) 18:28 Page 9 of 10
Availability of data and materials
Data available on request from the author but subject to permission from
the sponsor “Sheffield Teaching Hospitals.
Ethics approval and consent to participate
The trial received ethical approval from the North Sheffield Local Research
Ethics Committee (Ref No; 08/H1308/150). This study was registered on the
clinical trials database: NCT00735852. The trial also received approval from
the Medicine for Human Use Regulations Approval (MHRA). The study was
sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.
Consent for publication
Non-applicable.
Competing interests
None of the authors have any competing conflicts of interest.
Author details
1Academic Unit of Reproductive and Developmental Medicine, The
University of Sheffield, The Jessop Wing, Tree Root Walk, Sheffield, S10 3HY,
Sheffield, UK. 2Department of Obstetrics and Gynaecology, The Jessop Wing,
Tree Root Walk, Sheffield S10 3HY, UK. 3School of Social Sciences, Leeds
Beckett University, City Campus, Leeds LS1 3HE, UK. 4The University of New
South Wales, Royal Hospital for Women, Barker Street, Randwick NSW,
Sydney 2031, Australia.
Received: 5 October 2019 Accepted: 2 April 2020
References
1. Latthe P, Latthe M, Say L, Gulmezoglu M, Khan KS. WHO systematic review
of prevalence of chronic pelvic pain: a neglected reproductive health
morbidity. BMC Public Health. 2006;6:177.
2. Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes
associated with chronic pelvic pain and endometriosis. Hum Reprod
Update. 2014;20:737–47.
3. Triolo O, Lagana AS, Sturlese E. Chronic pelvic pain in endometriosis: an
overview. J Clin Med Res. 2013;5:153–63.
4. Giamberardino MA, Tana C, Costantini R. Pain thresholds in women with
chronic pelvic pain. Curr Opin Obstet Gynecol. 2014;26:253–9.
5. Morotti M, Vincent K, Brawn J, Zondervan KT, Becker CM. Peripheral changes
in endometriosis-associated pain. Hum Reprod Update. 2014;20:717–36.
6. Hoffman D. Central and peripheral pain generators in women with chronic
pelvic pain: patient centered assessment and treatment. Curr Rheumatol
Rev. 2015;11:146–66.
7. Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah J. Association of chronic
pelvic pain and endometriosis with signs of sensitization and myofascial
pain. Obstet Gynecol. 2015;125:719–28.
8. Moore JS, Gibson PR, Perry RE, Burgell RE. Endometriosis in patients with
irritable bowel syndrome: specific symptomatic and demographic profile, and
response to the low FODMAP diet. Aust N Z J Obstet Gynaecol. 2017;57:201–5.
9. Doggweiler R, Whitmore KE, Meijlink JM, Drake MJ, Frawley H, Nordling J,
Hanno P, Fraser MO, Homma Y, Garrido G, et al. A standard for terminology
in chronic pelvic pain syndromes: a report from the chronic pelvic pain
working group of the international continence society. Neurourol Urodyn.
2017;36:984–1008.
10. Saridogan E. Adolescent endometriosis. Eur J Obstet Gynecol Reprod Biol.
2017;209:46–9.
11. Won HR, Abbott J. Optimal management of chronic cyclical pelvic pain: an
evidence-based and pragmatic approach. Int J Women's Health. 2010;2:263–77.
12. Munoz-Hernando L, Munoz-Gonzalez JL, Marqueta-Marques L, Alvarez-
Conejo C, Tejerizo-Garcia A, Lopez-Gonzalez G, Villegas-Munoz E, Martin-
Jimenez A, Jimenez-Lopez JS. Endometriosis: alternative methods of
medical treatment. Int J Women's Health. 2015;7:595–603.
13. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin
and neurokinin B analogues. Nat Rev Endocrinol. 2013;9:451–66.
14. Ubuka T, Son YL, Tsutsui K. Molecular, cellular, morphological, physiological
and behavioral aspects of gonadotropin-inhibitory hormone. Gen Comp
Endocrinol. 2016;227:27–50.
15. https://bnf.nice.org.uk/drug/triptorelin.html - indicationsAndDoses.
16. Kim NY, Ryoo U, Lee DY, Kim MJ, Yoon BK, Choi D. The efficacy and
tolerability of short-term low-dose estrogen-only add-back therapy during
post-operative GnRH agonist treatment for endometriosis. Eur J Obstet
Gynecol Reprod Biol. 2011;154:85–9.
17. Zito G, Luppi S, Giolo E, Martinelli M, Venturin I, Di Lorenzo G, Ricci G.
Medical treatments for endometriosis-associated pelvic pain. Biomed Res
Int. 2014;2014:191967.
18. DiVasta AD, Feldman HA, Sadler Gallagher J, Stokes NA, Laufer MR,
Hornstein MD, Gordon CM. Hormonal add-Back therapy for females treated
with gonadotropin-releasing hormone agonist for endometriosis: a
randomized controlled trial. Obstet Gynecol. 2015;126:617–27.
19. Zheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P. Can postoperative GnRH
agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch
Gynecol Obstet. 2016;294:201–7.
20. Pinto-Almazan R, Segura-Uribe JJ, Farfan-Garcia ED, Guerra-Araiza C. Effects
of Tibolone on the central nervous system: clinical and experimental
approaches. Biomed Res Int. 2017;2017:8630764.
21. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic
pain. Pain. 1992;50:133–49.
22. Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, Chambers
WA, Smith WC. The chronic pain grade questionnaire: validation and
reliability in postal research. Pain. 1997;71:141–7.
23. Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an
endometriosis quality-of-life instrument: the endometriosis health Profile-30.
Obstet Gynecol. 2001;98:258–64.
24. Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV,
Daniels JR. Treatment of endometriosis with the GnRHa Deslorelin and add-Back
estradiol and supplementary testosterone. Biomed Res Int. 2015;2015:934164.
25. Al-Azemi M, Jones G, Sirkeci F, Walters S, Houdmont M, Ledger W. Immediate
and delayed add-back hormonal replacement therapy during ultra long GnRH
agonist treatment of chronic cyclical pelvic pain. BJOG. 2009;116:1646–56.
26. Nnoaham KE, Hummelshoj L, Webster P, d'Hooghe T, de Cicco NF, de Cicco
NC, Jenkinson C, Kennedy SH, Zondervan KT. World endometriosis Research
Foundation global study of Women's health c: impact of endometriosis on
quality of life and work productivity: a multicenter study across ten
countries. Fertil Steril. 2011;96:366–73 e368.
27. Souza CA, Oliveira LM, Scheffel C, Genro VK, Rosa V, Chaves MF, Cunha Filho JS.
Quality of life associated to chronic pelvic pain is independent of endometriosis
diagnosis--a cross-sectional survey. Health Qual Life Outcomes. 2011;9:41.
28. Tripoli TM, Sato H, Sartori MG, de Araujo FF, Girao MJ, Schor E. Evaluation of
quality of life and sexual satisfaction in women suffering from chronic
pelvic pain with or without endometriosis. J Sex Med. 2011;8:497–503.
29. Jia SZ, Leng JH, Shi JH, Sun PR, Lang JH. Health-related quality of life in
women with endometriosis: a systematic review. J Ovarian Res. 2012;5:29.
30. Kiykac Altinbas S, Bayoglu Tekin Y, Dilbaz B, Dilbaz S. Evaluation of quality of
life in fertile Turkish women with severe endometriosis. J Obstet Gynaecol.
2015;35:49–52.
31. Cox H, Henderson L, Andersen N, Cagliarini G, Ski C. Focus group study of
endometriosis: struggle, loss and the medical merry-go-round. Int J Nurs
Pract. 2003;9:2–9.
32. Matsui S, Yasui T, Kasai K, Keyama K, Kato T, Uemura H, Kuwahara A, Matsuzaki
T, Irahara M. Changes of liver enzymes and triglyceride during the menopausal
transition in Japanese women. J Obstet Gynaecol. 2016;36:806–11.
33. Ramachandran C, Fleisher D. Transdermal delivery of drugs for the
treatment of bone diseases. Adv Drug Deliv Rev. 2000;42:197–223.
34. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet
Neurol. 2008;7:354–61.
35. Ferrero S, Pretta S, Bertoldi S, Anserini P, Remorgida V, Del Sette M,
Gandolfo C, Ragni N. Increased frequency of migraine among women with
endometriosis. Hum Reprod. 2004;19:2927–32.
36. Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P. Migraine in women with
chronic pelvic pain with and without endometriosis. Fertil Steril. 2011;95:895–9.
37. MacGregor EA. Migraine headache in perimenopausal and menopausal
women. Curr Pain Headache Rep. 2009;13:399–403.
38. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and
weight change in elderly women: the Dubbo osteoporosis epidemiology
study. J Bone Miner Res. 1998;13:1458–67.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Alshehre et al. Reproductive Biology and Endocrinology           (2020) 18:28 Page 10 of 10
